4 results found.

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Clinical Trial using tivantinib; cetuximab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Randomized Phase II Trial of ARQ 197 (Tivantinib) /Cetuximab Versus Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer.
tivantinib; cetuximab; laboratory biomarker analysis

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Clinical Trial using afatinib; placebo; laboratory biomarker analysis

Eastern Cooperative Oncology Group - Recruiting 18 years or older.
- A Randomized, Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients With Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence.
afatinib; placebo; laboratory biomarker analysis

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Clinical Trial using TLR8 agonist VTX-2337; cetuximab; laboratory biomarker analysis; pharmacogenomic studies

University of Washington - Recruiting 18 years or older.
- Phase I Clinical Trial of VTX-2337, a Small Molecule Toll-Like Receptor 8 (TLR8) Agonist in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck (SCCHN).
TLR8 agonist VTX-2337; cetuximab; laboratory biomarker analysis; pharmacogenomic studies

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Clinical Trial using docetaxel; cisplatin; carboplatin; fluorouracil; bevacizumab

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer.
docetaxel; cisplatin; carboplatin; fluorouracil; bevacizumab